Advertisement
PAHC vs ZTS
Which Stock Would AI Choose? Phibro Animal Health Corporation (PAHC) vs. Zoetis Inc. (ZTS) Stock Comparison
Key Takeaways
- PAHC and ZTS operate in the animal health sector, with ZTS maintaining a larger global scale and broader product portfolio focused on companion and livestock animals.
- Recent market activity shows ZTS delivering stronger year-to-date returns compared to PAHC, though both stocks have experienced volatility tied to earnings and guidance updates.
- PAHC has seen leadership changes and raised fiscal outlooks amid sales growth in key segments, supporting relative stability in recent weeks.
- ZTS reported product launches and an acquisition in recent market activity while facing earlier guidance revisions that influenced analyst sentiment.
- Sector exposure to animal health provides both companies with similar macroeconomic drivers, yet differences in market capitalization and international reach create distinct risk-return profiles.
- Observable trends favor consistency in performance metrics for one over the other in the current environment, based on relative momentum and positioning.
Introduction
Investors and traders often compare PAHC and ZTS to evaluate opportunities within the animal health industry, where demand for veterinary pharmaceuticals, vaccines, and related products remains steady. This stock comparison highlights differences in scale, recent momentum, and market positioning that may appeal to those seeking exposure to defensive healthcare subsectors. Portfolio managers and active traders monitoring relative performance can use such analyses to assess diversification benefits or tactical allocations amid evolving economic conditions.
PAHC Overview and Recent Performance
Phibro Animal Health Corporation develops and markets animal health products, including vaccines, pharmaceuticals, and nutritional specialties primarily for livestock and poultry. In recent weeks, the stock has traded near levels around $34, reflecting modest year-to-date gains aligned with broader market benchmarks. Recent market activity included a new chief executive appointment and an upward revision to full-year earnings guidance following stronger-than-expected quarterly results earlier in the period. These developments contributed to positive sentiment shifts, though analyst price targets remain in the low $40 range, indicating measured expectations for further upside.
ZTS Overview and Recent Performance
Zoetis Inc. is a leading animal health company offering medicines, vaccines, diagnostics, and biopharmaceuticals for companion animals and livestock across more than 100 countries. The stock has recently closed near $75, posting substantial year-to-date appreciation that outpaced major indices. Recent market activity featured new product launches in Canada and the European Union, along with a strategic acquisition, which supported operational visibility. Earlier guidance adjustments and associated analyst revisions created temporary pressure, yet the company maintains a focus on innovation in high-growth areas such as dermatology and parasiticide portfolios.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across its platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance statistics tailored to prevailing market conditions. Only the most suitable and top-ranked bots based on backtested metrics and current suitability earn placement in this section, with available data often showing ranges of annualized returns, win rates, and drawdowns across different styles. All the AI trading bots have different trading styles, strategies, timeframes, performances, statistics, and sets of tickers they trade. Explore the curated options to identify bots aligned with specific objectives.
Head-to-Head Comparison
PAHC operates as a more focused player in animal health with emphasis on livestock segments, while ZTS benefits from greater scale, diversified revenue streams across companion and production animals, and extensive international operations. Growth drivers for PAHC center on nutritional specialties and recent leadership stabilization, contrasting with ZTS emphasis on innovation pipelines and recent geographic expansions. Recent momentum has favored ZTS in total returns, yet PAHC has shown resilience with fewer sharp corrections tied to earnings surprises. Risk factors include regulatory changes in antimicrobial use for both, though ZTS faces additional scrutiny from class-action matters stemming from prior periods. Sector exposure remains comparable, but market sentiment reflects ZTS larger capitalization attracting broader institutional attention alongside periodic volatility.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability in recent market activity, and relative positioning, Tickeron’s AI would currently assign a higher probabilistic preference to ZTS due to its stronger momentum profile and ongoing product catalysts, though PAHC offers potential advantages in valuation and steadier operational updates. Outcomes remain subject to evolving market dynamics and sector-specific developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PAHC is a Hold and ZTS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PAHC’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).
- PAHC’s FA Score: 1 green, 4 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PAHC’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).
- PAHC’s TA Score: 5 bullish, 5 bearish.
- ZTS’s TA Score: 4 bullish, 5 bearish.
Price Growth
PAHC (@Pharmaceuticals: Generic) experienced а -4.06% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -1.85% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.18%. For the same industry, the average monthly price growth was +3.17%, and the average quarterly price growth was +27.02%.
Reported Earning Dates
PAHC is expected to report earnings on Sep 02, 2026.
ZTS is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-1.18% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| PAHC | ZTS | PAHC / ZTS | |
| Capitalization | 1.38B | 31.3B | 4% |
| EBITDA | 222M | 4.06B | 5% |
| Gain YTD | -8.237 | -38.779 | 21% |
| P/E Ratio | 14.62 | 12.37 | 118% |
| Revenue | 1.5B | 9.53B | 16% |
| Total Cash | 77.5M | N/A | - |
| Total Debt | 787M | 9.24B | 9% |
PAHC | ZTS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 76 | 100 | |
SMR RATING 1..100 | 34 | 17 | |
PRICE GROWTH RATING 1..100 | 61 | 64 | |
P/E GROWTH RATING 1..100 | 98 | 95 | |
SEASONALITY SCORE 1..100 | 50 | 40 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ZTS's Valuation (10) in the Pharmaceuticals Generic industry is in the same range as PAHC (11) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PAHC’s over the last 12 months.
PAHC's Profit vs Risk Rating (76) in the Pharmaceuticals Major industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.
ZTS's SMR Rating (17) in the Pharmaceuticals Generic industry is in the same range as PAHC (34) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PAHC’s over the last 12 months.
PAHC's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as ZTS (64) in the Pharmaceuticals Generic industry. This means that PAHC’s stock grew similarly to ZTS’s over the last 12 months.
ZTS's P/E Growth Rating (95) in the Pharmaceuticals Generic industry is in the same range as PAHC (98) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew similarly to PAHC’s over the last 12 months.
| PAHC | ZTS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 73% | N/A |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 54% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 75% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 72% | 1 day ago 53% |
| Advances ODDS (%) | 17 days ago 74% | 4 days ago 50% |
| Declines ODDS (%) | 3 days ago 75% | 10 days ago 62% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 73% | 1 day ago 51% |
Advertisement
PAHC and
Correlation & Price change
A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.
| Ticker / NAME | Correlation To PAHC | 1D Price Change % | ||
|---|---|---|---|---|
| PAHC | 100% | +0.77% | ||
| ZTS - PAHC | 58% Loosely correlated | +3.13% | ||
| ELAN - PAHC | 47% Loosely correlated | +1.72% | ||
| AMRX - PAHC | 30% Poorly correlated | -2.21% | ||
| VTRS - PAHC | 29% Poorly correlated | -0.37% | ||
| LFCR - PAHC | 27% Poorly correlated | -0.84% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with PAHC. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then PAHC could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +3.13% | ||
| PAHC - ZTS | 58% Loosely correlated | +0.77% | ||
| ELAN - ZTS | 42% Loosely correlated | +1.72% | ||
| AMPH - ZTS | 36% Loosely correlated | +1.00% | ||
| SNDL - ZTS | 33% Loosely correlated | -0.79% | ||
| HLN - ZTS | 32% Poorly correlated | N/A | ||
More | ||||